Catalin Loghin.

Ted Feldman, M .D., Elyse Foster, M.D., Donald D. Glower, M.D., Saibal Kar, M.D., Michael J. Rinaldi, M.D., Peter S. Fail, M.D., Richard W. Smalling, M.D., Ph.D., Robert Siegel, M.D., Geoffrey A. Rose, M.D., Eric Engeron, M.D., Catalin Loghin, M.D., Alfredo Trento, M.D., Eric R. Skipper, M.D., Tommy Fudge, M.D., George V. Letsou, M.D., Joseph M. Massaro, Ph.D., and Laura Mauri, M.D. For the EVEREST II Investigators: Percutaneous Repair or Medical procedures for Mitral Regurgitation..

Notably, the between-group difference in the rate of driven target-vessel revascularization clinically, which was reported just in individuals with ischemic symptoms or signals, appeared to be smaller compared to the difference in the rate of ischemia-driven target-vessel revascularization and had not been significant. Fourth, 24 months of follow-up might not be enough to assess the late results after PCI with drug-eluting stents in comparison with CABG.32 Fifth, due to the restricted sample size, we can not fully investigate treatment results in various subpopulations. Finally, because the design of our trial needed that patients meet particular prespecified criteria, our results may not be generalizable to the entire population of sufferers with unprotected left primary coronary artery stenosis.